Evidence map›Paper›PMID 35589813›Full record

ArticleNature communications2022

Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro.

Leiping Zeng, Yanxia Liu, Xammy Huu Wrynla, Timothy R Abbott, Mengting Han, Yanyu Zhu, Augustine Chemparathy, Xueqiu Lin, Xinyi Chen, Haifeng Wang and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. NBiomolecules · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Targeting the SARS-CoV-2 reservoir in long COVID.The Lancet. Infectious diseases · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 7 institutions in 2 countries.

Leiping Zeng *Department of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-6421-0950
Yanxia Liu *Department of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Xammy Huu WrynlaDepartment of Molecular and Cellular Biology, University of California, Berkeley, CA, 94720, USA.ORCID http://orcid.org/0000-0002-7532-8356
Timothy R AbbottDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-7404-811X
Mengting HanDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Yanyu ZhuDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-8681-976X
Augustine ChemparathyDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Xueqiu LinDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Xinyi ChenDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Haifeng WangDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.
Draven A RaneDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-9445-7260
Jordan M SpatzDepartment of Pediatrics, Stanford University, Stanford, CA, 94305, USA.
Saket JainUniversity of California San Francisco, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0002-8655-2951
Arjun RustagiDepartment of Medicine, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-6921-1012
Benjamin PinskyDepartment of Medicine, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-8751-4810
Adrianna E ZepedaSynthego Corporation, Redwood City, CA, USA.
Anastasia P KadinaSynthego Corporation, Redwood City, CA, USA.
John A WalkerSynthego Corporation, Redwood City, CA, USA.
Kevin HoldenSynthego Corporation, Redwood City, CA, USA.ORCID http://orcid.org/0000-0002-3091-4124
Nigel TempertonViral Pseudotype Unit, Medway School of Pharmacy, Chatham, Kent ME4 4TB, UK.ORCID http://orcid.org/0000-0002-7978-3815
Jennifer R CochranDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-6532-9873
Annelise E BarronDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-0735-6873
Michael D ConnollyLawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.ORCID http://orcid.org/0000-0002-1817-8136
Catherine A BlishDepartment of Medicine, Stanford University, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-6946-7627
David B LewisDepartment of Pediatrics, Stanford University, Stanford, CA, 94305, USA.
Sarah A StanleyDepartment of Molecular and Cellular Biology, University of California, Berkeley, CA, 94720, USA. sastanley@berkeley.edu.
Marie F La RussaDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA. mlarussa@stanford.edu.
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, CA, 94305, USA. stanley.qi@stanford.edu.ORCID http://orcid.org/0000-0002-3965-3223
Stanford University · USSynthego (United States) · USChan Zuckerberg Biohub San Francisco · USUniversity of California, Berkeley · USLawrence Berkeley National Laboratory · USMedway School of Pharmacy · GBUniversity of California, San Francisco · US

Funding

Modeling early SARS-CoV-2 pathogenesis in human lung organoids and slice culturesK08AI163369 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUSTAGI, ARJUN · 2022 to 2025
$772k
NIAID NIH HHS K08 AI163369
6 · The paper itself

Abstract

A major challenge in coronavirus vaccination and treatment is to counteract rapid viral evolution and mutations. Here we demonstrate that CRISPR-Cas13d offers a broad-spectrum antiviral (BSA) to inhibit many SARS-CoV-2 variants and diverse human coronavirus strains with >99% reduction of the viral titer. We show that Cas13d-mediated coronavirus inhibition is dependent on the crRNA cellular spatial colocalization with Cas13d and target viral RNA. Cas13d can significantly enhance the therapeutic effects of diverse small molecule drugs against coronaviruses for prophylaxis or treatment purposes, and the best combination reduced viral titer by over four orders of magnitude. Using lipid nanoparticle-mediated RNA delivery, we demonstrate that the Cas13d system can effectively treat infection from multiple variants of coronavirus, including Omicron SARS-CoV-2, in human primary airway epithelium air-liquid interface (ALI) cultures. Our study establishes CRISPR-Cas13 as a BSA which is highly complementary to existing vaccination and antiviral treatment strategies.

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsHumansLiposomesNanoparticlesAntiviral AgentsLipid NanoparticlesLiposomes

Identifiers

PMID35589813
PMCPMC9119983
OpenAlexW4280605463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.